Why the study?
Does long-term oral ketanserin cause QT prolongation and torsade de pointes?
Does long-term oral ketanserin cause QT prolongation and torsade de pointes?
Long-term oral treatment with ketanserin is associated with significant QTc prolongation and carries a potential hazard of torsade de pointes.
Answers are grounded in this paper and cite their sources.
May warrant QTc monitoring during long-term ketanserin; leaves open torsades risk magnitude in larger prospective cohorts.
A 65-year-old man with arterial hypertension received oral treatment with Ketanserin, a new drug, during a period of five months. He developed marked QT interval prolongation and have several Stokes-Adams attacks. A Holter recording obtained during one of these episodes showed torsade de pointes ventricular tachycardia. The arrhythmias occurred during maximum QT interval prolongation. The correlation between Ketanserin and QT interval prolongation was evaluated by using several Holter studies during administration and withdrawal of the drug. The effect of Ketanserin on the QTc interval was analyzed retrospectively in six patients who had been taking the drug orally. Following a period of four to eight months, the QTc interval was prolonged by the drug (5 to 31%, mean 17%) in five patients. We conclude that torsade de pointes is a potential hazard of long-term treatment with Ketanserin.
No takes yet. Share an insight, caveat, or question.
Aldariz et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: